Atripla Approved As First Once-Daily, Single-Tablet HIV Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
The Bristol/Gilead combination product will launch within seven business days.
You may also be interested in...
Gilead Quad’s Side Effects Profile, Novel Agents To Get Advisory Committee Review
FDA’s Antiviral Drugs Advisory Committee takes up the four-drug HIV-1 regimen, which includes two new agents, on May 11. The firm hopes to be able to sell the combination in part on its favorable side effects profile if the product is approved.
BMS, Gilead Atripla Alliance To Include European Commercialization
Merck & Co. gives up exclusive ex-U.S. rights to any product containing efavirenz in some European countries to allow the deal.
BMS, Gilead Atripla Alliance To Include European Commercialization
Merck & Co. gives up exclusive ex-U.S. rights to any product containing efavirenz in some European countries to allow the deal.